OCTREOTIDE ACETATE

PRODUCT IDENTIFICATION

CAS RN

EINECS RN

FORMULA

MOLE WEIGHT

CLASSIFICATION

PHYSICAL AND CHEMICAL PROPERTIES

PHYSICAL STATE

MELTING POINT

BOILING POINT

DENSITY

SOLUBILITY IN WATER

pH

VAPOR DENSITY

REFRACTIVE INDEX

FLASH POINT

INCOMPATIBLE MATERIALS

Strong acids, Strong bases

Carbon monoxide, Carbon dioxide, Nitrogen oxides. Sulphur oxides

NFPA RATINGS

SAFETY

HAZARD NOTES

EYE

May cause eye irritation.

SKIN

May be harmful if absorbed through skin. May cause skin irritation.

INGESTION

May be harmful if swallowed.

INHALATION

May be harmful if inhaled. May cause respiratory tract irritation.

CHRONIC

TRANSPORT & REGULATORY INFORMATION

UN NO.

HAZARD SYMBOL

RISK PHRASES

SAFETY PHRASES

Octreotide is a hormone that occurs naturally in the body. It is used to treat carcinoid syndrome, which is seen in patients with carcinoid or neuroendocrine tumors. These tumors cause the body to overproduce certain hormones, and these hormones in turn can lead to symptoms collectively known as "carcinoid syndrome". Common symptoms include: flushing (90% of patients), diarrhea (75%), abdominal cramping (51%), and abnormalities of the heart valves (53%) possibly leading to right heart failure. Octreotide works to reduce the production of these hormones and thereby decrease the symptoms.

• Octreotide is available in two forms, a fast/short-acting form called Sandostatin, and a long-acting form called Sandostatin LAR.
• Octreotide is used to control symptoms in gastro-entero-pancreatic (GEP) endocrine tumors, such as insulinoma, gastrinoma, VIPoma, glucagonoma, somatostatinoma, and carcinoid tumors.
• Octreotide is also used to treat acromegaly, also known as gigantism, and chemotherapy induced diarrhea. (http://www.oncolink.com/treatment/)

Octreotide is a synthetic octapeptide analogue with a similar pharmacologic action to that of somatostatin, but with a prolonged duration of action. It has a half-life of 100 minutes after subcutaneous administration. Its effects include the inhibition of the release of pituitary growth hormone and secretion of peptides (for example, insulin, glucagon, gastrin, and other peptides) and serotonin produced in the gastroenteropancreatic (GEP) endocrine system. It alters gastrointestinal motility, splanchnic blood flow, and gastrointestinal absorption. Somatostatin analogues have also been used in an attempt to suppress tumour growth through the inhibition of cell proliferation, stimulation of apoptosis, inhibition of the release of circulating tumour growthpromoting humoral effectors, and reduction in the blood supply to tumours. (http://www.cadth.ca/media/pdf/)

The effect of Octreotide (SMS 201-995), synthetic somatostatin analogue on small intestinal and colonic fluid secretion induced respectively by cholera toxin (CT) and deoxycholic acid (DCA) was investigated in rabbits using in vivo isolated loops. After exposure to CT and DCA, marked fluid accumulation was observed in the small intestinal and colonic loops, along with elevation of jejunal and colonic mucosal cyclic AMP concentrations. Octreotide inhibited CT and DCA induced small intestinal and colonic secretion, dose-dependently. This anti-secretory effect was observed after both intramuscular and oral administration of octreotide. In contrast, octreotide did not affect the elevated mucosal cyclic AMP concentrations. These results suggest that octreotide inhibits CT and DCA induced intestinal secretion, and this anti-secretory effect is produced by affecting processes beyond cyclic AMP formation.(http://www.ncbi.nlm.nih.gov/)

Gastric Antisecretory Agents

SALES SPECIFICATION

APPEARANCE

pass (HPLC)

PURITY

98.0% min

RELATED SUBSTANCES

2.0% max (total impurity), 1.0% max (Individual impurity)

15.0% max

PACKING

PRICE INFORMATION